Formulation and in vitro assessment of minoxidil niosomes for enhanced skin delivery. - Wikidata - awgldk - TriplyDB

Formulation and in vitro assessment of minoxidil niosomes for enhanced skin delivery.

Formulation and in vitro assessment of minoxidil niosomes for enhanced skin delivery.

http://www.wikidata.org/entity/Q34977824

about

New ethanol and propylene glycol free gel formulations containing a minoxidil-methyl-β-cyclodextrin complex as promising tools for alopecia treatment.Characterisation and Skin Distribution of Lecithin-Based Coenzyme Q10-Loaded Lipid Nanocapsules Nanotechnology in cosmetics: Opportunities and challenges.Preparation and evaluation of minoxidil foamable emu oil emulsion QbD-based carbopol transgel formulation: characterization, pharmacokinetic assessment and therapeutic efficacy in diabetes.Development of nanovesicular systems for dermal imiquimod delivery: physicochemical characterization and in vitro/in vivo evaluation.Niosomal gel of lornoxicam for topical delivery: in vitro assessment and pharmacodynamic activity.Tolterodine Tartrate Proniosomal Gel Transdermal Delivery for Overactive Bladder Charged liposomes as carriers to enhance the permeation through the skin.Niosomes as a propitious carrier for topical drug delivery.Recent advances in non-ionic surfactant vesicles (niosomes): self-assembly, fabrication, characterization, drug delivery applications and limitations.Colloidal drug delivery system: amplify the ocular delivery.In vitro and in vivo investigation for optimization of niosomal ability for sustainment and bioavailability enhancement of diltiazem after nasal administration.Formulation of tretinoin-loaded topical proniosomes for treatment of acne: in-vitro characterization, skin irritation test and comparative clinical study.Enhanced in vitro cellular uptake of P-gp substrate by poloxamer-modified liposomes (PMLs) in MDR cancer cells.Serratiopeptidase Niosomal Gel with Potential in Topical Delivery.Comparative study on the effects of some polyoxyethylene alkyl ether and sorbitan fatty acid ester surfactants on the performance of transdermal carvedilol proniosomal gel using experimental design.Etodolac Containing Topical Niosomal Gel: Formulation Development and Evaluation.Niosomal carriers enhance oral bioavailability of carvedilol: effects of bile salt-enriched vesicles and carrier surface charge.Vancomycin-eluting niosomes: a new approach to the inhibition of staphylococcal biofilm on abiotic surfaces.Formulation of niosomal gel for enhanced transdermal lopinavir delivery and its comparative evaluation with ethosomal gel.Preformulation, formulation, and in vivo efficacy of topically applied apomine.pH-sensitive pHLIP® coated niosomes.In Vitro and In Vivo Evaluation of Niosomal Formulation for Controlled Delivery of Clarithromycin Niosomes as a potential drug delivery system for increasing the efficacy and safety of nystatin.Niosomal encapsulation of ethambutol hydrochloride for increasing its efficacy and safety.Nano-proniosomes enhancing the transdermal delivery of mefenamic acid.Novel in situ gelling ocular inserts for voriconazole-loaded niosomes: design, in vitro characterisation and in vivo evaluation of the ocular irritation and drug pharmacokinetics.Novel non-ionic surfactant proniosomes for transdermal delivery of lacidipine: optimization using 2(3) factorial design and in vivo evaluation in rabbits.Minoxidil Induction of VEGF Is Mediated by Inhibition of HIF-Prolyl Hydroxylase.Minoxidil Skin Delivery from Nanoemulsion Formulations Containing Eucalyptol or Oleic Acid: Enhanced Diffusivity and Follicular Targeting.Germacrone and sesquiterpene-enriched extracts from Curcuma aeruginosa Roxb. increase skin penetration of minoxidil, a hair growth promoter.Improved hepatoprotective activity of silymarin via encapsulation in the novel vesicular nanosystem bilosomes.Potential enhancement and targeting strategies of polymeric and lipid-based nanocarriers in dermal drug delivery.Effect of formulation compositions on niosomal preparations.Optimization of minoxidil microemulsions using fractional factorial design approach.Paclitaxel and curcumin coadministration in novel cationic PEGylated niosomal formulations exhibit enhanced synergistic antitumor efficacy.Formulation by design-based proniosome for accentuated transdermal delivery of risperidone: in vitro characterization and in vivo pharmacokinetic study.Formulation and evaluation of proniosomes containing lornoxicam.Transdermal delivery of oxybutynin chloride proniosomal gels for the treatment of overactive bladder.

P2860

Q30781549-C1866AB8-878E-4DF7-A5FD-F70E773F5485 Q34205341-7295C160-B930-4407-8F4B-7C291CB85E5B Q34296083-027599B7-BA55-4C30-AE67-3C3D1B8FCCF5 Q35029649-EC9F3ABF-535F-43A6-9F4B-C3E1F2F94B1A Q35208156-E13F4B73-A3DA-4A86-9563-63274B0FC551 Q35635404-EF6CD075-0246-4A6A-A61A-8702E665751D Q37126399-F39FD68B-A3BB-49C5-AF51-A8BB342DA53E Q37290722-E454703A-35C5-4FCE-8EB8-55F98A5B76D1 Q37873946-EB3DC3E7-335F-436A-9461-F42F09E829DA Q38068500-71B16BE3-4659-44CC-9077-FF9EBEF080A9 Q38155210-D41604A7-60BD-4B30-A81C-25DE64D00854 Q38217270-804BEB5B-FBAA-478F-9C92-4B2231D4E74F Q38760966-9C11DFA6-1B78-4831-9900-4344396FB7E6 Q39378497-7F2D167C-6012-4053-A01D-83B1F7177636 Q39504361-4426E492-98BA-416D-B8FE-E4564ECEE3B6 Q41496823-F2D179BD-FA16-44BB-B2B4-5DDD35184497 Q41500018-BBF06E68-74EC-440B-B425-ED7E13B2CE4D Q41817566-717EFCF1-185D-4E5D-9D57-E51126FEA1FE Q41871280-55AA77E3-041D-41B5-8914-026B1FF21667 Q41885249-451D40FE-C05B-4658-90DB-93E1435738B7 Q41988134-1F982AD1-F8D0-4E19-A5E7-961D58CD3F40 Q42149365-AB174A49-6E13-430D-B7F8-FAE29EA2C374 Q42623230-D4B4EC0D-B4BB-4E54-83B0-3FE4B148B7CB Q42753033-E395B84C-B15D-4A9C-B3AB-B72EB88E4745 Q44837755-C9524C66-19CF-4EDD-AE66-1D8145C86D42 Q46528246-53AC8B00-3C28-4D77-BE50-21A893D9C8E8 Q46754307-28522C9F-01C6-4BB2-84B2-B37CE8CFDC98 Q46844328-90F82A4F-30E0-4457-BCCB-D92C98404538 Q46902877-07711894-3E77-4296-9638-CF1C4CF36C68 Q47218522-70B032B5-797C-452D-B8FD-15126D4E80A9 Q47700876-05BA72DC-98D0-44DC-8CA3-86DC6E3359EB Q48265876-5DC03C67-4AE9-4A22-91C6-B01DC4463882 Q48324641-A4CD98EF-23C2-4D8E-879E-4D7ACA7831CE Q50072089-4D239FD1-3858-47AD-B180-36E8F7D591A1 Q50249189-5A2A5F60-625D-487A-A045-E282A10F7D46 Q51024616-D98899CF-B125-410E-93E9-F1C4E1FC21C7 Q51731998-589793B9-AECA-46A6-A5E0-6248105F6B7A Q51756206-211C97C4-3FBF-4AA7-84FE-4E106A77A0DA Q53089921-D5FDE45B-E4CF-498C-8891-804B2A6CE0AD Q53254489-215AF2A9-F86F-42BD-9EFD-6F4F563652CB

P2860

Formulation and in vitro assessment of minoxidil niosomes for enhanced skin delivery.

http://www.wikidata.org/entity/Q34977824

description

2009 nî lūn-bûn

@nan

2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Formulation and in vitro assessment of minoxidil niosomes for enhanced skin delivery.

@ast

Formulation and in vitro assessment of minoxidil niosomes for enhanced skin delivery.

@en

Formulation and in vitro assessment of minoxidil niosomes for enhanced skin delivery.

@nl

type

label

Formulation and in vitro assessment of minoxidil niosomes for enhanced skin delivery.

@ast

Formulation and in vitro assessment of minoxidil niosomes for enhanced skin delivery.

@en

Formulation and in vitro assessment of minoxidil niosomes for enhanced skin delivery.

@nl

prefLabel

Formulation and in vitro assessment of minoxidil niosomes for enhanced skin delivery.

@ast

Formulation and in vitro assessment of minoxidil niosomes for enhanced skin delivery.

@en

Formulation and in vitro assessment of minoxidil niosomes for enhanced skin delivery.

@nl

P1433

Q34977824-34AB12AF-53A8-4BE4-88D0-7B0AA3BCCA42

P1476

Q34977824-BAE6A6BF-B9DC-462C-B989-C3E2D63F94DF

P2093

Q34977824-00ED34C5-4D9A-47A6-B48E-C5B170C50415

Q34977824-02E3E95C-585A-48FC-B1A7-DFC10B7A9F99

Q34977824-48DC223B-B2D6-4A57-981B-C2A85C30D006

Q34977824-55B90315-0A36-4B0D-849B-6F5871FDE75C

Q34977824-5A393FCC-7889-4B3A-88AC-A7C3EDF0693E

Q34977824-9A81206E-DF45-4F61-BA07-35CA6E874CC0

Q34977824-9C940D92-8F52-49C6-BB4E-0BA98074926A

Q34977824-AA997290-3DED-46EE-BE9F-487588C6FC05

Q34977824-AF3C5E68-703D-4F1B-B6B5-371816020C79

Q34977824-D9DF4158-6309-4227-93AE-AB5CCC95BDE4

P304

Q34977824-4295E21B-8482-4F54-A190-5DBB359D5204

P31

Q34977824-5A8F51F0-C0AF-443D-AE52-EAE63610B6F7

P356

Q34977824-4E8B1C4E-84DA-46E9-B62E-CE4220C22173

P407

Q34977824-8783D33D-9CD7-4317-A092-A3E4C5CD52A2

P433

Q34977824-070AE7B4-E046-440B-8E37-6A6B5D106CF0

P478

Q34977824-BB46E8F1-BC50-49B9-8668-CF7E90772ECA

P50

Q34977824-F5C8A1C0-1ED4-4A87-B6E2-C04B10C25A6B

P577

Q34977824-52311B8F-009A-4B4A-8E4C-185C05BB4105

P5875

Q34977824-A6079110-4A7F-4504-AE14-D743D31DB19B

P698

Q34977824-D62C042C-0D64-4B7E-9EA6-949AF8D788A8

P356

J.IJPHARM.2009.04.020

P1433

International Journal of Pharmaceutics

P1476

Formulation and in vitro assessment of minoxidil niosomes for enhanced skin delivery

@en

P2093

Bong Kyu Yoo

http://www.w3.org/2001/XMLSchema#string

Chul Soon Yong

http://www.w3.org/2001/XMLSchema#string

Dae-Duk Kim

http://www.w3.org/2001/XMLSchema#string

Dong Hoon Oh

http://www.w3.org/2001/XMLSchema#string

Han-Gon Choi

http://www.w3.org/2001/XMLSchema#string

Jong Oh Kim

http://www.w3.org/2001/XMLSchema#string

Jong Soo Woo

http://www.w3.org/2001/XMLSchema#string

Jung Sun Kim

http://www.w3.org/2001/XMLSchema#string

Prabagar Balakrishnan

http://www.w3.org/2001/XMLSchema#string

Won Mo Lee

http://www.w3.org/2001/XMLSchema#string

P304

1-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.IJPHARM.2009.04.020

http://www.w3.org/2001/XMLSchema#string

P407

P433

1-2

http://www.w3.org/2001/XMLSchema#string

P478

377

http://www.w3.org/2001/XMLSchema#string

P50

Srinivasan Shanmugam

P577

2009-04-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24360128

http://www.w3.org/2001/XMLSchema#string

P698

19394413

http://www.w3.org/2001/XMLSchema#string